Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701126 | 0.81 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL12063279 | 0.81 | CHRNA7 (0.83) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL7045728 | 0.80 | CHRNA7 (0.85) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL701068 | 0.77 | CHRNA7 (0.72) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL701302 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL31375368 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL26748340 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL699884 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL699598 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL703479 | 0.75 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1053236-A1 | PYRDIYL-BRIIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000034276-A1 | PYRIDYL-BRIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | CHRNA7 11/4885CHRNB2 9/4885CHRNA4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.